To ensure ethical pharmaceutical practices in the supply chain of weight loss drug (GLP-1), the Drugs Controller of India has intensified its regulatory surveillance against the drug’s unauthorised sale and promotion.
“With the recent introduction of multiple generic variants of GLP-1-based weight loss drugs in the Indian market, concerns have emerged regarding their on-demand availability through retail pharmacies, online platforms, wholesalers, and wellness clinics. These drugs, when used without proper medical supervision, may lead to serious adverse effects and related health risks,’’ said the Health Ministry in a release on Tuesday (March 24, 2026).
Sale of fake obesity drugs driven by high prices, weight-loss desire prompts health concern: Lancet
Taking cognisance of the situation, India’s drugs controller, in collaboration with State regulators, has initiated a series of targeted actions to curb possible malpractices across the pharmaceutical supply chain and prevent unauthorised sales and use.
On March 10, a comprehensive advisory was issued to all manufacturers, explicitly prohibiting surrogate advertisements and any form of indirect promotion that could mislead consumers or encourage off-label usage.
